australia's next csl?, page-3

A great article, Ash81. The profitability data looks reasonable. Margins based on a royalty model should easily exceed 50%, even taking into account manufacturing and other costs (note only micrograms are needed for each dose). Even if the royalty is only at 5%, the earnings potential is clearly huge - and not too far off either. P/E of 0.5 using 5% royalty, or 0.25 using 10%. And improving by 25% each year!!! Why doesn't TIS and its great product get more publicity??